Literature DB >> 16187969

Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for Helicobacter pylori eradication.

Jean Spénard1, Christian Aumais, Julie Massicotte, Jean-Sébastien Brunet, Claude Tremblay, Michael Grace, Marc Lefebvre.   

Abstract

AIMS: To evaluate the effects of food and formulation on the pharmacokinetics of bismuth biskalcitrate, metronidazole and tetracycline when combined in a new 3-in-1 single capsule (BMT) for eradication of Helicobacter pylori.
METHODS: In a randomized, 3 x 3 cross-over design, 23 healthy males received one dose of BMT in the fed and fasting states and equivalent doses of the three drugs given together but as separate capsules while fasting. Bioequivalence was evaluated according to 90% confidence intervals (CIs) of ratios of geometric least square means for C(max), AUC(t), and AUC(infinity).
RESULTS: With respect to food, none of the three drugs met bioequivalence guidelines. Bismuth had lower limit CIs ranging from 12% for C(max) to 25% for AUC(infinity). The corresponding values for tetracycline were 59% and 51%. Metronidazole had a lower limit CI of 74% for C(max). With respect to formulation, bismuth had lower limits of CIs ranging from 39% for C(max) to 50% for AUC(t) and higher limits of 146% for AUC(t), metronidazole met bioequivalence guidelines, and tetracycline had lower limits of CIs between 72% for AUC(t) and 74% for AUC(infinity).
CONCLUSIONS: Food significantly decreased the relative bioavailability of each drug but formulation was without effect. This decrease may be beneficial when a local gastric action is needed, as confirmed by a near 90% eradication rate when this combined capsule is administered with food to treat gastro-duodenal local infection by H. pylori.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16187969      PMCID: PMC1884817          DOI: 10.1111/j.1365-2125.2005.02441.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Bismuth-based quadruple therapy for Helicobacter pylori - a single triple capsule plus lansoprazole.

Authors:  W A De Boer; R J Van Etten; B A Van De Wouw; P M Schneeberger; A H Van Oijen; J B Jansen
Journal:  Aliment Pharmacol Ther       Date:  2000-01       Impact factor: 8.171

2.  The influence of coffee with milk and tea with milk on the bioavailability of tetracycline.

Authors:  H Jung; A A Peregrina; J M Rodriguez; R Moreno-Esparza
Journal:  Biopharm Drug Dispos       Date:  1997-07       Impact factor: 1.627

3.  Effect of food on doxycycline absorption.

Authors:  N A Kshirsagar; P S Ankalesaria
Journal:  J Postgrad Med       Date:  1987-07       Impact factor: 1.476

Review 4.  Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics. Part 1: tetracyclines.

Authors:  M Barza; R T Schiefe
Journal:  Am J Hosp Pharm       Date:  1977-01

Review 5.  Clinical pharmacokinetics of metronidazole.

Authors:  E D Ralph
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

6.  A single drug for Helicobacter pylori infection: first results with a new bismuth triple monocapsule.

Authors:  W A de Boer; R J van Etten; P M Schneeberger; G N Tytgat
Journal:  Am J Gastroenterol       Date:  2000-03       Impact factor: 10.864

7.  Bismuth accumulates in the body during treatment with tripotassium dicitrato bismuthate.

Authors:  C J Gavey; M L Szeto; C U Nwokolo; J Sercombe; R E Pounder
Journal:  Aliment Pharmacol Ther       Date:  1989-02       Impact factor: 8.171

8.  Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study.

Authors:  C O'Morain; T Borody; A Farley; W A De Boer; C Dallaire; R Schuman; J Piotrowski; C A Fallone; G Tytgat; F Mégraud; J Spénard
Journal:  Aliment Pharmacol Ther       Date:  2003-02       Impact factor: 8.171

9.  Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial.

Authors:  Loren Laine; Richard Hunt; Hala El-Zimaity; Bich Nguyen; Michael Osato; Jean Spénard
Journal:  Am J Gastroenterol       Date:  2003-03       Impact factor: 10.864

10.  Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects.

Authors:  P G Welling; P A Koch; C C Lau; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1977-03       Impact factor: 5.191

View more
  3 in total

Review 1.  A Review of Food-Drug Interactions on Oral Drug Absorption.

Authors:  Jianyuan Deng; Xiao Zhu; Zongmeng Chen; Chun Ho Fan; Him Shek Kwan; Chi Ho Wong; Ka Yi Shek; Zhong Zuo; Tai Ning Lam
Journal:  Drugs       Date:  2017-11       Impact factor: 9.546

2.  Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies.

Authors:  Antoine Tarral; Séverine Blesson; Olaf Valverde Mordt; Els Torreele; Daniela Sassella; Michael A Bray; Lionel Hovsepian; Eric Evène; Virginie Gualano; Mathieu Felices; Nathalie Strub-Wourgaft
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

3.  Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.

Authors:  Ki Young Huh; Hyewon Chung; Yu Kyong Kim; SeungHwan Lee; Siddharth Bhatia; Yohei Takanami; Ryou Nakaya; Kyung-Sang Yu
Journal:  Br J Clin Pharmacol       Date:  2021-06-26       Impact factor: 3.716

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.